In conclusion, these findings suggest that TMEM59L, as a membrane transport‐associated protein, may serve as a novel target for modulating drug resistance in CRC through membrane signaling and DNA repair pathways. The gene discussed is TMEM59L; the disease is colorectal carcinoma.